ARTICLE | Product Development
Solving AAV’s one-and-done problem: ASGCT highlights
Strategies to enable redosing and overcome pre-existing immunity could help revive interest in rare disease gene therapy
May 12, 2026 1:12 AM UTC
Solving AAV’s redosing problem could change the economics of rare disease gene therapy and reignite industry interest in a modality that has fallen out of favor. The concept, a hot topic at this week’s ASGCT conference, is creeping closer to reality.
The 2026 American Society of Gene and Cell Therapy (ASGCT) meeting will feature at least 12 preclinical presentations that describe strategies to enable repeat dosing or overcome pre-existing immunity to AAV vectors...